Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for MRKR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 -3.716M
March 31, 2026 -1.404M
December 31, 2025 -1.900M
September 30, 2025 -2.736M
June 30, 2025 -1.878M
March 31, 2025 -5.500M
December 31, 2024 -4.703M
September 30, 2024 1.198M
June 30, 2024 -3.568M
March 31, 2024 -3.837M
December 31, 2023 -2.368M
September 30, 2023 -1.128M
June 30, 2023 -7.057M
March 31, 2023 -5.888M
December 31, 2022 -6.305M
September 30, 2022 -7.646M
June 30, 2022 -0.7947M
March 31, 2022 -12.23M
December 31, 2021 -4.858M
September 30, 2021 -6.516M
June 30, 2021 -6.910M
March 31, 2021 -8.996M
December 31, 2020 -6.219M
September 30, 2020 -4.239M
June 30, 2020 -4.352M
Date Value
March 31, 2020 -4.050M
December 31, 2019 -4.561M
September 30, 2019 -5.664M
June 30, 2019 -4.179M
March 31, 2019 -3.880M
December 31, 2018 -6.163M
September 30, 2018 -3.572M
June 30, 2018 -2.399M
March 31, 2018 -2.346M
December 31, 2017 -2.478M
September 30, 2017 -2.025M
June 30, 2017 -2.012M
March 31, 2017 -1.924M
December 31, 2016 -1.754M
September 30, 2016 -1.972M
June 30, 2016 -1.954M
March 31, 2016 -0.8298M
December 31, 2015 -0.851M
September 30, 2015 -1.665M
June 30, 2015 -0.8132M
March 31, 2015 -1.014M
December 31, 2014 -0.6692M
September 30, 2014 -0.9065M
June 30, 2014 -0.238M
March 31, 2014 -0.3735M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Krystal Biotech, Inc. 74.79M
Ironwood Pharmaceuticals, Inc. 58.28M
SELLAS Life Sciences Group, Inc. -7.588M
Rezolute, Inc. -13.74M
ADMA Biologics, Inc. 29.54M

Cash from Operations (Quarterly) Related Metrics